

A Study on Significance of Risk Assessment in Cardiovascular Diseases

Dr. V. Satyanarayana¹, B. Sowjanya², D. Abhishekh³, M. Nandini⁴,
SK. Ummarsharief⁵

^{1,2,3,4}Professor and Students Department of Pharmacy Practice MAM College of Pharmacy

ABSTRACT

Due to poor diet and lifestyle choices that negatively impact people's health, cardiovascular diseases (CVDs) are the major cause of death and morbidity in India. CVD rates are expected to rise in the future due to a lack of knowledge and preventive measures. One tactic to lessen the risk of CVD is to take a combo pill (Simvastatin, Lisinopril, Hydrochlorothiazide, Aspirin), which contains antiplatelet, cholesterol-lowering, and blood pressure-lowering agents, respectively.

Methodology: Participants who have at least one risk of CVD (dyslipidemia or hypertension) are chosen, and they are given the combo medication once daily for eight weeks. Once a week, their lipid profiles, ECG, blood pressure, and other parameters are taken for analysis.

Results & Conclusion: The combination pill's effectiveness was evaluated by looking at how much it reduced TG, TC, LDL-C, and blood pressure while simultaneously raising HDL levels. Consequently, it was discovered that the combo pill had the highest level of safety with the fewest possible adverse effects, making it effective in treating individuals with hypertension, dyslipidemia, or coronary artery disease.

Keywords: Cardiovascular disease, Dyslipidemia, Hypertension, Combination pill

1. INTRODUCTION

The subcontinent of India is expected to see a cardiovascular disease (CVD) epidemic due to changes in lifestyle and demography, as well as the impact of undernutrition during children on adult diseases [1]. Over the past 20 years, there has been a steady rise in the prevalence of ischemic heart disease in India [2,3]. Comprehensive public health initiatives at the individual and population levels will be necessary to reduce CVD [4]. Nowadays, nearly all of these high-risk people should be treated with three groups of CVD medications: antiplatelet, blood pressure lowering, and cholesterol reducing medicines, according to international guidelines [5,6,7].

Potential to improve adherence with new, lowcost combination medication:

Treatment gaps can be caused by a variety of factors, such as low adherence brought on by the cost, complexity, and stigma associated with taking one or more separate cardiovascular (CV) drugs, as well as ineffective dissemination and acceptance of guidelines [8,9]. Easy-to-afford combination medications could be a significant opportunity to enhance the availability and adherence to efficient CV treatment [10,11]. A strategy of impersonal interventions such as dietary salt reduction and the use of combination therapy based on absolute risk can reduce CV events by more than 50% [12].

DYSLIPIDEMIA

Dyslipidemia is defined as abnormality in lipid metabolism leads to increased elevation of disorder of lipoprotein metabolism, including lipoprotein over production or deficiency [13].

There is strong relationship between elevated cholesterol levels and the genesis of coronary heart disease. Coronary artery disease yet remains one of the major killers in the current society [14].

Hyperlipidemia can be divided into,

1. Primary Hyperlipidemia,
2. Secondary Hyperlipidemia

1. Primary hyperlipidemia (familial; hereditary): It is genetically determined

Types of primary hyperlipidemia [15]

Class	Increased lipoprotein	Synonym
Type I	↑Chylomicrons	Familial chylomicronemia
Type IIa Type IIb	↑LDL ↑LDL & VLDL	Familial Hypercholesterolemia Familial combined hyperlipidemia
Type III	↑IDL	Familial dis-beta lipoproteinemia
Type IV	↑VLDL	Familial hypertriglyceridemia
Type V	↑VLDL & Chylomicrons	Familial mixed hyperlipidemia

2.Secondary hyperlipidemia: Secondary hyperlipidemia is attributed to some other reasons like Diabetes mellitus, hyperthyroidism, chronic renal failure, glucagon storage disease, stress etc.,

Optimal, Borderline, and high levels for each component [16]

ELIMENT	OPTIMAL	BORDERLINE	HIGH RISK
LDL cholesterol	<100	130-159	160+
HDL cholesterol	>60	35-45	<35
Triglycerides	<150	150-199	>200
Total cholesterol	<200	200-239	>240
Cholesterol to HDL ratio	<4	5	>6

Diagnosis: serum lipid profile is used for measuring total cholesterol, TG & HDL cholesterol and calculated LDL cholesterol and VLDL. **Treatment**

strategies [17]:

1. Dietary therapy
2. Exercise and stress reduction.
3. Drug therapy

- **Statins-HMG CoA reductase inhibitors:** Lovastatin, Simvastatin, Atorvastatin.
- **Bile acids binding resins:** Cholestyramine, Colesevelam
- **Fibrates & derivatives-** Benzfibrate, Clofibrate, Ciprofibrate.
- **Nicotinic acid**
- **Fish oil**
- **Cholesterol absorption inhibitor:** Ezetimibe

Adverse effects of statins: “Rhabdomyolysis” is most serious adverse effect from statin use, though it occurs quite rarely (less than 0.1%).

Adverse drug reactions: Headache, dizziness, physically weak or unusually tired, sleep problems, low blood platelet count, feeling sick, diarrhea, indigestion.

II. EPIDEMIOLOGY

In recent years the total global mortality has been having the dominance of chronic diseases as major contributors. By 2005, the total number of CVD deaths mainly (coronary heart disease, rheumatic heart disease and stroke) had increased globally to 17.5 million from 14.4million in 1990. In those 5.7million were attributed to stroke and 7.6million to coronary heart disease. Out of those the low income and middle countries had more than 80% of deaths. There will be 20million CVD deaths 2015, accounting for 30% of all deaths worldwide was estimated by the World Health Organization (WHO). By 2030, researches project that non-communicable diseases will account for more than three-quarters of deaths worldwide; in low-income countries more deaths will be responsible because of CVD than any other infectious diseases. Thus, the largest single contributor to global mortality will be CVD and will continue to dominate mortality trends in the future [4].

III. OBJECTIVES

- To select the cardiovascular patient with lipid profile abnormality.
- Comparison of lipid profile with standard guidelines NCEP ATP III.
- To categorize the patients based on the lipid profile.
- To find out the risk factors for cardiovascular disease.

IV. METHODOLOGY

Patients aged 18-75 years with at least one factor for CVD namely Hypertension $\geq 139/89$ mm of Hg and $\leq 180/110$ mm of Hg according to JNCVII guidelines and lipid profile LDL-C ≥ 130 mg/dl or LDL-C >100 mg/dl with CVD equivalent or patients with Coronary Artery Disease or high CV risk factors given combination pill i.e., Aspirin 75mg, Hydrochlorothiazide 12.5mg, Simvastatin 10mg, Lisinopril 5mg.

Low Dose pill taken once daily increased to medium dose, if necessary. The selected eligible patients are subjected for screening of blood and urine samples which were sent for the baseline safety investigation every 1st,4th ,8th and 12th week .In order to determine the efficacy of the drug combination the principle parameters are observed along with the other parameters, induces; blood pressure 120/80 mm of Hg LDL-cholesterol <100 mg/dl, Total triglycerides <200 mg/dl the heart rate is 60-70 beats/minute .The major parameter to assess cholesterol, and Total glycerides levels in 4 visits were evaluated by ANOVA. The comparative significance is tested and should be less than 0.05.and triglycerides levels in 4 visits, which were collected and evaluated by using SPSS.

V. RESULTS AND DISCUSSION

Total number of patients enrolled were 30 as per the study protocol. The total number of patients successfully completed the study were 27 as per the inclusion and exclusion criteria. Their LDL-C, Triglycerides, total cholesterol and HDL levels are compared with means of 4 visits.

DATA- ANALYSIS

The major parameters for assessment of efficacy of the drug combinations were LDL cholesterol

	LDL-C		Triglycerides		Total Cholesterol		HDL	
	Visit-1	Mean Visit 2,3and4	Visit-1	Mean Visit 2,3and4	Visit-1	Mean Visit 2,3and4	Visit-1	Mean Visit 2,3and4
Moderate Hypertensive (n=23)	150.60±5.19	102.96±2.936***	209.21±16.047	153.30±8.95**	217.60±6.25	169.4±4.30***	41.39±2.04	49.73±1.99**
Severe Hypertensive (n=4)	221.5±6.33	181.8±6.414**	156.0±3.93	99.3±7.52**	216.75±8.51	149.12±11.8**	35.50±3.06	57.9±3.64**

Efficacy of Combination Pill on Hyperlipidemia

n values are given as mean ±SEM

** , *** Values are statistically significant compared to Visit 1(Base line) at P<0.01, P<0.001 respectively.

DISCUSSION:

The efficacy of combination pill on moderate systolic HTN patients was shown that P<0.05 (P=0.001). The combination pill was considered as effective. So, the combination pill shows higher efficacy on systolic and diastolic BP higher levels and doesn't show any side effects during and 4 visits. And also, the combination pill on levels on TC levels in patients show P<0.05 (P=0.001), LDL-C levels in patients shows P<0.05 (P=0.001), Triglycerides levels in patients shows P<0.05 (P=0.004) and HDL levels in patients shows P<0.05 (P=0.005). So that the combination pills shows higher efficacy and the drug has increased the levels of TC, LDL-C, Triglycerides and HDL levels and doesn't show any side effects during 4 visits.

VI. CONCLUSION

The regular check-up mast cell process may improve the condition of cardiovascular patients. Therefore, combination pills have been found to have maximum safety with minimal side effects and are useful in treating patients with high blood pressure, dyslipidemia, or coronary artery disease.

1. Reddy K. Primordial prevention of coronary heart disease in India-challenges and opportunities. Prev Med. 1999;29:119e123.
2. Padmavathi S. Prevention of heart disease in India in the 21st century e need for a concerted effort. Indian Heart J. 2002;54:103.
3. Institute of Medicine (US) committee on preventing the Global Epidemic of Cardiovascular Disease: Meeting the Challenges in Developing Countries; Fuster V, Kelly BB, editors. National Academic Press (US); 2010.
4. Position Statement of the American Diabetes Association. Aspirin therapy in diabetes. Diabetes Ca-

re. 2003;26:87e88.

5. Tracy-Lea Lada, Strategies to improve adherence to medications for cardiovascular diseases in socioeconomically disadvantaged DOI: 10.35629/7781-090113421365 | Impact Factor value 7.429
ISO 9001: 2008 Certified Journal Page 1347

REFERENCE

1. Jhon W. McEvoy,...Roger S. Blumenthal, Dyslipidemia in Hypertension: A companion to Braunwald's Heart disease (Third Edition), 2018.
2. Sara Mosca, Dyslipidemia diagnosis and treatment: Risk Stratification in children and Adolescents. J Nutr Metab. 2022; 2022: 4782344.
3. Sundus F Hantoosh, Hyperlipidemia Classification 2 Brain Biochemistry and Disorders-Book 122;2:2020
4. Jennifer G. Robinson, MD, MPH Lipid Management/ Secondary Hyperlipidemia/lipid and lipoprotein basics. 2024;7;2.
5. Gail Underbakke RD, MS, Patrick E. McBride MD, MPH, in Integrative Medicine (Third Edition), 2012.